skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8847

Delayed release pancrelipase for treatment of pancreatic exocrine insufficiency associated with chronic pancreatitis

Review

(2155) Views  (1044) Full article downloads

Authors: Devi Mukkai Krishnamurty, Atoosa Rabiee, Sanjay B Jagannath, Dana K Andersen

Published Date July 2009 Volume 2009:5 Pages 507 - 520
DOI: http://dx.doi.org/10.2147/TCRM.S3196

Devi Mukkai Krishnamurty,1 Atoosa Rabiee,2 Sanjay B Jagannath,1 Dana K Andersen2

Johns Hopkins University School of Medicine; 1Department of Medicine; 2Department of Surgery, Johns Hopkins Hospital, Baltimore, MD, USA; 2Johns Hopkins University School of Medicine, Johns Hopkins Bayview Medical Center, Baltimore, MD, USA

Abstract: Pancreatic enzyme supplements (PES) are used in chronic pancreatitis (CP) for correction of pancreatic exocrine insufficiency (PEI) as well as pain and malnutrition. The use of porcine pancreatic enzymes for the correction of exocrine insufficiency is governed by the pathophysiology of the disease as well as pharmacologic properties of PES. Variability in bioequivalence of PES has been noted on in vitro and in vivo testing and has been attributed to the differences in enteric coating and the degree of micro-encapsulation. As a step towards standardizing pancreatic enzyme preparations, the Food and Drug Administration now requires the manufacturers of PES to obtain approval of marketed formulations by April 2010. In patients with treatment failure, apart from evaluating drug and dietary interactions and compliance, physicians should keep in mind that patients may benefit from switching to a different formulation. The choice of PES (enteric coated versus non-enteric coated) and the need for acid suppression should be individualized. There is no current standard test for evaluating adequacy of therapy in CP patients and studies have shown that optimization of therapy based on symptoms may be inadequate. Goals of therapy based on overall patient presentation and specific laboratory tests rather than mere correction of steatorrhea are needed.

Keywords: pancreatic exocrine insufficiency, chronic pancreatitis, pancreatic enzyme supplement








Readers of this article also read:

Delayed release pancrelipase for the treatment of pancreatic exocrine insufficiency associated with cystic fibrosis
Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors
Safety and efficacy of telbivudine for the treatment of chronic hepatitis B
Antimicrobial prophylaxis in colorectal surgery: focus on ertapenem
Lasofoxifene for the prevention and treatment of postmenopausal osteoporosis
Information technology in pharmacovigilance: Benefits, challenges, and future directions from industry perspectives
Review of topiramate for the treatment of epilepsy in elderly patients
Helicopter emergency medical services accident rates in different international air rescue systems
Enzyme replacement therapy for pancreatic insufficiency: present and future
Development of the knowledge of fertility and fertility preservation scale